5 results about "Lipid A synthesis" patented technology

This invention relates to a method for rapidly screening filamentous fungi that produce high levels of triglycerides and polyunsaturated fatty acids, belonging to the field of microbial technology. The method employs a two-stage screening strategy of "resistance primary screening – fluorescence secondary screening." In the primary screening stage, strains with strong lipid synthesis capabilities are initially screened by adding a combination of phytocyanin and quizalofop-p-ethyl inhibitors to the culture medium. In the secondary screening stage, cellophane culture technology and Nile red fluorescence staining are combined to quantitatively assess the triglyceride content of the colonies, achieving rapid and non-destructive screening. This method is simple to operate, highly efficient, and shows a significant positive correlation between fluorescence intensity and triglyceride content. It is suitable for mutagenesis breeding and industrial strain selection of oil-producing filamentous fungi such as *Morchella alpineensis*.

The present application belongs to the field of microalgae biotechnology, microalgae culture regulation and high-value lipid bio-manufacturing, and specifically relates to a method for improving microalgae biomass and eicosapentaenoic acid (EPA) yield by regulating amino acids, which takes microalgae capable of synthesizing EPA as a culture object, adds exogenous amino acids or amino acid combinations to the culture system under non-stress culture conditions containing sufficient inorganic nitrogen source, regulates photosynthesis, growth metabolism and lipid synthesis process of the microalgae, and simultaneously improves microalgae biomass and EPA volumetric yield; by adding specific exogenous amino acids or amino acid combinations under the condition of sufficient nutrition culture, the present application realizes synchronous promotion of microalgae growth and EPA accumulation. Different from traditional methods of relying on stress such as nitrogen deficiency to induce lipid accumulation, the present application can improve microalgae biomass, photosynthetic performance, pigment yield and EPA volumetric yield without significantly inhibiting cell growth and photosynthetic activity.

The invention belongs to the technical field of transplanted vascular remodeling diagnosis and treatment, and discloses application of a reagent for inhibiting or detecting Fasn and a medicine for preventing and / or treating transplanted vascular remodeling. Experimental research discovers that a group of novel macrophages capable of self-synthesizing lipid exist in the transplantation blood vessel reconstruction process, and Fasn is remarkably activated, so that intracellular lipid accumulation is caused, and the macrophages are promoted to be converted into foam cells. In-vitro studies show that by inhibiting the activity of the Fasn enzyme or down-regulating the expression of the Fasn enzyme, the transformation of macrophages to foam cells can be obviously inhibited, and the synthesis of lipid in cells can be reduced. Based on the discovery, the nucleic acid medicine constructed by adopting the siRNA is used for treating and / or relieving transplanted vascular remodeling. In-vivo experiments further prove that the nucleic acid medicine can remarkably inhibit intimal hyperplasia of transplanted blood vessels and reduce the neointimal / medial membrane ratio, so that the therapeutic effect is achieved. The method has a good application prospect.

This invention relates to a composition for repairing the lipid barrier and its application in sensitive skin care, belonging to the field of cosmetic technology. The composition includes *Plasmodium purpureus* extract, flaxseed extract, senna-based glycosides, and oat extract. The rational combination of these four components not only promotes lipid synthesis but also ensures effective lipid transport and prevents the oxidative degradation of newly synthesized lipids. By covering the entire lipid metabolism process, it achieves a long-lasting and stable barrier repair effect, and can be applied to the repair of the lipid barrier in people with sensitive skin. Efficacy testing shows that the *Plasmodium purpureus* extract, flaxseed extract, senna-based glycosides, and oat extract in the composition can synergistically enhance the composition's antioxidant and lipid synthesis-promoting capabilities, while effectively promoting skin barrier repair and increasing skin moisture content, exhibiting significant skin-soothing and repairing effects, making it highly suitable for people with sensitive skin.

The application discloses application of a Piezo1 agonist in preparation of a medicine for treating meibomian gland dysfunction, and belongs to the technical field of biological medicines. The application first proposes Piezo1 as a brand-new medicine target for treating meibomian gland dysfunction. Experiments prove that the Piezo1 agonist can directly target the meibomian gland, effectively enhance the glycolysis level of cells, and then promote cell differentiation and lipid synthesis, so as to restore the gland function and treat meibomian gland dysfunction. The application provides a brand-new thought and strategy for research and development of a medicine for treating meibomian gland dysfunction, and has a wide clinical application prospect.